CFAH VHIO – Vall d'Hebron Institute of Oncology

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

VHIO’s Enriqueta Felip takes up the reins as SEOM President (2021-2023)

22/10/2021|Comments Off on VHIO’s Enriqueta Felip takes up the reins as SEOM President (2021-2023)

VHIO investigators co-author new ESMO Clinical Practice Guideline with evidence-based recommendations for the treatment of metastatic breast cancer

21/10/2021|Comments Off on VHIO investigators co-author new ESMO Clinical Practice Guideline with evidence-based recommendations for the treatment of metastatic breast cancer

VHIO-led research reveals a driver of adaptive resistance to therapies targeting KIT mutations in GIST

21/10/2021|Comments Off on VHIO-led research reveals a driver of adaptive resistance to therapies targeting KIT mutations in GIST

RAD51 as a biomarker of homologous recombination deficiency & predictor of clinical outcomes in patients with triple-negative breast cancer

13/10/2021|Comments Off on RAD51 as a biomarker of homologous recombination deficiency & predictor of clinical outcomes in patients with triple-negative breast cancer

Posttranslational modification as a regulator of protein function: a review of latest insights & the signposting of next directions

06/10/2021|Comments Off on Posttranslational modification as a regulator of protein function: a review of latest insights & the signposting of next directions

Elena Garralda’s ESMO On target column: considering the concordance of treatment recommendations between central consensus & MTBs

05/10/2021|Comments Off on Elena Garralda’s ESMO On target column: considering the concordance of treatment recommendations between central consensus & MTBs

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS